Update on Guardian System (4) Transmitter 30 July 2026 The National Diabetes Services Scheme has recently issued an announcement regarding the discontinuation of the Guardian System (4) Transmitter (NDSS Code 985) from 1 September 2026. The Guardian System 4 Transmitter will still be available for those who use the MiniMed™ 780G insulin pump system with Guardian Link (4) and will no longer be approved for standalone use with the Guardian app. Support is available during this transition for people who currently rely on the Guardian System (4) as their continuous glucose monitoring (CGM) system. Diabetes Australia remains committed to supporting people living with diabetes through technology changes and ensuring access to reliable information, education and guidance. We encourage anyone affected by this change to begin planning early and to seek advice from their diabetes healthcare team to support a smooth transition before 1 September 2026. For further information, contact: NDSS Helpline: 1800 637 700 Medtronic Australia: 1800 668 670
Media releases 17 August 2026 Diabetes Australia to deliver Insulin Pump Program supporting children and young people Diabetes Australia has been appointed to deliver the Commonwealth-funded Insulin Pump Program (IPP). Continue Reading
Media releases 14 August 2026 Beyond blood glucose: New national partnership to measure how Australians with diabetes are really doing For the first time, the Australian Unity Wellbeing Index will be used to build the most complete picture yet of how diabetes affects Australian’s lives beyond clinical outcomes and health system costs, thanks to a partnership between Diabetes Australia, Deakin University, and the Australian Unity Support Foundation. Continue Reading
Media releases 13 August 2026 PMOS in spotlight for diabetes prevention A new partnership between Diabetes Australia and the Medibank Better Health Research Hub will support Monash University to develop a primary care model to better detect and prevent type 2 diabetes in women living with polyendocrine metabolic ovarian syndrome (PMOS). Continue Reading